[Board of directors]
Krupa Rajur, MD. CEO, President, & Board Member
Krupa received her MD degree in internal medicine from Tufts University School of Medicine and completed her fellowship in Nephrology from Brown University RI. Currently she serves as a nephrologist at Southern New Hampshire Medical Center in Nashua & Dartmouth Hitchcock Medical Center in Manchester, NH.
Raj Rajur, PhD, Executive Director, Founder, & Board Member
Dr. Rajur holds a PhD degree in synthetic and organic chemistry. Dr. Rajur's academic career includes appointments at the Southwestern Medical Center in Dallas, Boston College, Northeastern University, Massachusetts General Hospital and
Harvard Medical School.
In the industrial sector, he has held scientific and managerial positions at ArQule and Millipore Corporations. He has authored more than 25 papers in peer-reviewed journals and holds 3 US patents.
John L. Brooks III, Chairman & Board Member
John is a well-known life sciences executive. He is the managing director of Healthcare Capital, LLC. Previously President & Chief Executive Officer of the Joslin Diabetes Center. He has co-founded 7 life sciences companies including Insulet (PODD), & Prism Venture Partners. He was previously the Emerging Business Group General Manager at Pfizer/Valleylab.
Nandan Padukone, Ph.D, MBA Board Member
Nandan is an Entrepeneur-in-Resident at T1D Fund, Strategic Advisor at Joslin Diabetes Center, & Mentor/Catalyst at MIT Deshpande Center and MassBio. Dr. Padukone has been Joslin's Senior Vice President, Innovation from 2012-2018. He's facilitated several start-up companies and helped achieve funding from SBIRs, foundations, angel groups, and VCs. He was previously President & CEO of Nuvera Biosciences (2005-2012), & President of Silico Insights (2000-2005).
Bill Cummings Board Member
Bill Cummings has been employed in sales and marketing positions with Vick Chemical Company (Vaporub, etc.). He founded Cummings Properties and built/restored dozens of large & very large commercial structures. Cummings Properties provides business homes for more than 2,000 MA businesses & organizations. He has served 10 years as a charter trustee of Tufts and is a former overseer of Tufts Medical School & Director of Winchester Hospital. He was named 1998 Real Estate Entrepreneur of the Year for New England by Ernst & Young, LLP. He was also awarded Tufts Distinguished Service Award "for service to Tufts, his community, and his profession." He has been recognized as one of the 50 Most Influential Bostonians by Boston Business Journal.
David Lucchino, CEO, Frequency, Chair, MassBio
David is Co-founder, President, & Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience. Previously, he was President & Chief Executive Officer of Entrega Bio, Semprus Biosciences, and Senior Executive of Polaris Partners.
Dale Larson, Entrepeneur
Dale is Director of Commercial Initiatives at Draper Laboratory and is currently working on technologies in the human organ systems, automated bioprocessing for cellular therapies, rapid diagnostics, & neurotechnology. He's received support from sponsors including: DARPA-BTO, the NIH, DTRA, and pharma & medtech companies. Previously, he worked at Johnson & Johnson, Arthur D. Little, & Bell Telephone Laboratory.
Raj Rajur, CEO, CreaGen, Founder, C2I
Dr. Rajur is co-founder and CEO of CreaGen and C2I Accelerator. He is a medical chemistry specialist and has vast experience in drug design and drug development. He has previously held executive roles at ArQule, and Millipore.
Martha Farmer, Board, Northshore Innoventures
Martha Farmer is Founder, CEO, and Board Member of Northshore Innoventures. She is advisor for MassBio and MassConnect. She has also held senior executive roles at Baxter, biotech companies.
Gary Magnant, Venture Advisor, CEO, Tribiotica
Gary is a Boston-based serial biotechnology entrepeneur and has been successful in starting, building, & selling life science companies for 25+ years. He developed the venture engineering process and has co-founded several biotech companies including: Owl Scientific, Sage Science, & Thrive Bioscience. Gary is currently interim CEO & venture engineer at TriBiotica. He is a former chairman & member of the Board of Trustees of Stoneridge Montessori (now Harborlight Montessori) and a recipient of the Hallowell Award.
Andrew Jay, Ph.D, Entrepeneur
Dr. Jay is an entrepeneur, board member & co-founder of instrumentation, diagnostics, and device companies. He is advisor to venture funds and overseas groups. He is also former managing director of Siemens Ventures.
Glenn Miller, Ph.D, Partners Healthcare
Dr. Miller is Innovation's Market Sector Leader for Radiology, Anethesiology, Neurology, Neurosurgery, and Psychiatry at Partners Healthcare. Previously he was President of CDx Vision, and Companion Diagnostics. He has nearly 30 years of experience in clinical laboratory industry & personalized medicine. He also previously served as Executive VP & Chief Technology Officer of Molecular MD; VP & Head of Personalized Healthcare and Biomarker Strategy; Portfolio & Alliances for AstraZeneca Pharmaceuticals; and leading Genzyme Analytical Services as VP & GM.
Raj Manchanda, Innovation Portfolio Leader, Gates MRI
Dr. Raj Manchanda is currently Innovation Portfolio Leader at Bill and Melinda Gates Medical Research Institute (Gates MRI) in Cambridge. Raj holds a Ph. D in Chemistry from Yale University, a M.Sc. in Chemistry from the Indian Institute of Technology, and a B.Sc. in Chemistry from Delhi University. He was also an Anna Fuller postdoctoral fellow at MIT. Previously he was at Frequency Therapeutics where he was Chief Development Officer. Prior to Frequency, Raj was VP of Neurodegeneration and Early-Stage Therapeutics at Biogen. He also held leadership positions at Diatide, Avid Radiopharmaceuticals, Perkin Elmer Life and Analytical Sciences, and URL Pharmaceuticals.
Mark Tebbe, Ph.D, Chief Technology Officer, Quench Bio
Mark co-founded Quench Bio with Atlas Venture and Arix Bioscience where he is the Chief Technology Officer. He is also an Atlas EIR. Formerly, Mark was VP and Head of Drug Discovery at Quartet Medicine. Mark has >24 years of experience in drug discovery and development and is a co-inventor of Incivek ™ (Telaprevir), an HCV protease inhibitor. Before Quartet, he was VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Mark worked with Eli Lilly over a 16-year career as head of chemistry in Hamburg, Germany and Research Triangle Park, North Carolina as well as Global Head of Operations for the discovery chemistry group. He obtained his Ph. D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.